Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation

Cancer Genetics and Cytogenetics

Volumn 199, Issue 1, 2010, Pages 56-61

  Oshikawa, Gaku ^a   Kurosu, Tetsuya ^a   Arai, Ayako ^a   Murakami, Naomi ^b   Miura, Osamu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD33 ANTIGEN; CD34 ANTIGEN; HYDROXYUREA; IMATINIB; MICROSOMAL AMINOPEPTIDASE; ABL BCR FUSION PROTEIN, HUMAN; ABL-BCR FUSION PROTEIN, HUMAN; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA;

AGED; ARTICLE; BONE MARROW CELL; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; KARYOTYPING; LEUKOCYTOSIS; MOLECULAR CLONING; MOLECULAR PROBE; MYELOBLAST; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECURRENT DISEASE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TETRAPLOIDY; THROMBOCYTOPENIA; ADOLESCENT; ADULT; BONE MARROW; CELL CLONE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYPLOIDY; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; DNA MUTATIONAL ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHILADELPHIA CHROMOSOME; PIPERAZINES; POLYPLOIDY; PYRIMIDINES; RNA, MESSENGER; RNA, NEOPLASM; TIME FACTORS;

EID: 77951884988     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.01.018     Document Type: Article

References (37)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
2. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
3. Pane F., Frigeri F., Sindona M., Luciano L., Ferrara F., Cimino R., Meloni G., Saglio G., Salvatore F., Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88:2410-2414.
4. Pane F., Intrieri M., Quintarelli C., Izzo B., Muccioli G.C., Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002, 21:8652-8667.
5. Arana-Trejo R.M., Ruiz Sanchez E., Ignacio-Ibarra G., Baez de la Fuente E., Garces O., Gomez Morales E., Castro Granados M., Ovilla Martinez R., Rubio-Borja M.E., Solis Anaya L., Herrera P., Delgado Llamas J., Kofman S. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 2002, 24:145-150.
6. Ito T., Tanaka H., Tanaka K., Ito K., Kyo T., Dohy H., Kamada N., Kimura A. Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with micro-BCR-ABL (e19a2) transcript. Br J Haematol 2004, 126:752-753.
7. Goh H.G., Hwang J.Y., Kim S.H., Lee Y.H., Kim Y.L., Kim D.W. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res 2006, 148:249-256.
8. Wada H., Mizutani S., Nishimura J., Usuki Y., Kohsaki M., Komai M., et al. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res 1995, 55:3192-3196.
9. Yamagata T., Mitani K., Kanda Y., Yazaki Y., Hirai H. Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia. Br J Haematol 1996, 94:370-372.
10. Wilson G., Frost L., Goodeve A., Vandenberghe E., Peake I., Reilly J. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. Blood 1997, 89:3064.
11. Haskovec C., Ponzetto C., Polak J., Maritano D., Zemanova Z., Serra A., Michalova K., Klamova H., Cermak J., Saglio G. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 1998, 103:1104-1108.
12. How G.F., Tan L.T., Lim L.C. Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction-is it truly a benign disease?. Leukemia 1998, 12:1166-1167.
13. Polak J., Koza V., Cetkovsky P., Haskovec C. An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr. Bone Marrow Transplant 2000, 25:1109-1110.
14. Bernasconi P., Calatroni S., Boni M., Cavigliano P.M., Pagnucco G., Bernasconi C. p230 does not always predict a mild clinical course in myeloid malignancies: e19a2 bcr/abl fusion transcript with additional chromosome abnormalities in a patient with acute monoblastic leukemia (M5a). Haematologica 2001, 86:320-321.
15. Bertorelle R., Bonaldi L., Bianchini E., Ramazzina E., Del Mistro A., Zamboni S., Chieco-Bianchi L., Paolini R. The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild type. Leukemia 2001, 15:2003-2004.
16. Martinez-Lopez J., Ayala R., Albizua Q. Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases. Haematologica 2002, 87. ELT35.
17. Ohsaka A., Hoshino S., Kobayashi M., Kudo H., Kawaguchi R. Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a). Br J Haematol 2002, 118:251-254.
18. Verstovsek S., Lin H., Kantarjian H., Saglio G., De Micheli D., Pane F., Garcia-Manero G., Intrieri M., Rotoli B., Salvatore F., Guo J.Q., Talpaz M., Specchia G., Pizzolo G., Liberati A.M., Cortes J., Quackenbush R.C., Arlinghaus R.B. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002, 94:2416-2425.
19. Wang L., Seale J., Woodcock B.E., Clark R.E. e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts. Leukemia 2002, 16:1562-1563.
20. Lee J.J., Kim H.J., Kim Y.J., Lee S., Hwang J.Y., Kim Y.L., Kim D.W. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 2004, 18:1539-1540.
21. Boeckx N., Jansen M.W., Haskovec C., Vandenberghe P., van der Velden V.H., van Dongen J.J. Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR. Leukemia 2005, 19:1292-1295.
22. Mondal B.C., Majumdar S., Dasgupta U.B., Chaudhuri U., Chakrabarti P., Bhattacharyya S. e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases. J Clin Pathol 2006, 59:1102-1103.
23. Andrikovics H., Nahajevszky S., Szilvasi A., Bors A., Adam E., Kozma A., Kajtar B., Barta A., Poros A., Tordai A. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. Hematol Oncol 2007, 25:143-147.
24. Li X., Yang J., Chen X., Liu J., Li H., Zheng J., He Y., Chen Z., Huang S. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript. Cancer Genet Cytogenet 2007, 176:166-168.
25. Popovici C., Charbonnier A., Gisserot O., Aguilon P., Remy V., Olschwang S., Mozziconacci M.J. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML. Leuk Res 2008, 32:361-362.
26. Yamamoto M., Kurosu T., Kakihana K., Mizuchi D., Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun 2004, 319:1272-1275.
27. Cortes J., O'Dwyer M.E. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004, 18:671-684. x.
28. Sokal J.E., Gomez G.A., Baccarani M., Tura S., Clarkson B.D., Cervantes F., et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988, 72:294-298.
29. Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107:76-94.
30. Meza Espinoza J.P., Judith Picos Cardenas V., Gutierrez-Angulo M., Gonzalez Garcia J.R. Secondary chromosomal changes in 34 Philadelphia-chromosome-positive chronic myelocytic leukemia patients from the Mexican West. Cancer Genet Cytogenet 2004, 148:166-169.
31. Hirata J., Umemura T., Nishimura J., Sadamura S., Sato H., Nawata H. Double t(1;7)(p36;p11) in a megakaryocytic crisis of chronic myelogenous leukemia with variant t(5;9;22). Cancer Genet Cytogenet 1993, 65:107-110.
32. Morita Y., Takahashi A., Yamamoto K., Miki T., Murakami N., Miura O. Secondary near-tetraploidy with double der(15)t(15;17) in acute promyelocytic leukemia in relapse. Cancer Genet Cytogenet 2004, 149:131-136.
33. Testa J.R., Oguma N., Pollak A., Wiernik P.H. Near-tetraploid clones in acute leukemia. Blood 1983, 61:71-78.
34. Adeyinka A., Wei S., Sanchez J. Loss of 17p is a major consequence of whole-arm chromosome translocations in hematologic malignancies. Cancer Genet Cytogenet 2007, 173:136-143.
35. Lessard M., Helias C., Struski S., Perrusson N., Uettwiller F., Mozziconacci M.J., Lafage-Pochitaloff M., Dastugue N., Terre C., Brizard F., Cornillet-Lefebvre P., Mugneret F., Barin C., Herry A., Luquet I., Desangles F., Michaux L., Verellen-Dumoulin C., Perrot C., Van den Akker J., Lespinasse J., Eclache V., Berger R. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?. Cancer Genet Cytogenet 2007, 176:1-21.
36. Ganem N.J., Pellman D. Limiting the proliferation of polyploid cells. Cell 2007, 131:437-440.
37. Inami M., Inokuchi K., Yamaguchi H., Nakayama K., Watanabe A., Uchida N., Tanosaki S., Dan K. Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression. Int J Hematol 2006, 84:346-353.